Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.
about
Familial aggregation of autoimmune disease in juvenile dermatomyositisType I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosisIRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosusGene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositisThe unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies.Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients.Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestryInterferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseasesMycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis.Type 1 interferons and myositis.Pathogenesis of dermatomyositis: role of cytokines and interferon.Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis: a meta-analysis.Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damageAssociations between TNF-α-308A/G polymorphism and susceptibility with dermatomyositis: a meta-analysis.Interferon alpha as a primary pathogenic factor in human lupusThe autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes.Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients.Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cellsType I interferon pathway in adult and juvenile dermatomyositis.Gene-expression-guided selection of candidate loci and molecular phenotype analyses enhance genetic discovery in systemic lupus erythematosus.The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease courseFunctional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patientsInhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease.Type I interferons in systemic autoimmunity.Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.Immunological biomarkers in dermatomyositis.The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot studyMuscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.Detection of interferon alpha protein reveals differential levels and cellular sources in disease.Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis.Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies
P2860
Q28235854-DE787019-59DD-4668-81E1-F75341341EF4Q28251763-BB4A4E61-2C73-4E41-9FDF-52CAF095DA94Q28253129-882101E1-CD8E-488E-9ABE-D1DE1FF0EDE1Q28287170-CDD3924B-46F9-40D6-84DC-368357023220Q33939981-62BAEAF3-AE38-473D-9864-BA9185B97244Q34022033-BD822EDA-978D-4D05-A21C-7A0117EB9A8FQ34110737-48230E6E-8D7B-4E44-BD24-378F4A2F7AE5Q34123569-D8525978-92BB-49A4-B999-9463FAB9F5F8Q34185599-9630F8E6-C452-4722-A752-DC2B52D4141AQ34214035-E8A5C0D4-D348-4536-86AE-4AFB5E856BAEQ34350190-51530620-1582-409A-8FA7-1A47CD2337CBQ34626955-4A1CBE25-6514-4758-8E82-E364F65A63E0Q34745794-F661DD38-B6D7-4D97-824A-5E599779AE77Q35125063-AE006EB1-54E7-4594-98EB-4AD93EE40E05Q35220862-18BE717C-450D-41C4-9764-14F11E4ACCB9Q35603587-BC697DEC-6E47-48D9-855A-B8D0C31D099DQ35832505-148AA13D-22E8-4E0E-BCFB-2A238E67E914Q35832527-98BDF53D-DC39-4BA3-826C-06C39D1F5E64Q35854122-2C292B3D-D322-49F4-B3D9-590E6E7CC65EQ35907790-B08E5083-4E2F-49BA-B7C1-FD8F37B609FFQ36228760-09A51318-1CEA-417D-9DA3-84B49D21C101Q36338717-2AF493CD-D103-4B13-B94E-7B78CFD5C0E5Q36434501-798625BF-4B11-49D1-9838-67F99C605890Q37543386-FAA40E5D-FB98-4727-829C-3A8478361CCCQ37543452-AA3F75CF-6963-4A0C-9783-DECC7C3A9211Q37666293-A1ACB037-D07C-44B6-B4A8-45F2492DA7C1Q37713727-3C2AAB24-BC7F-4A08-B61A-A1F580763B7CQ37808291-C7E152B9-651D-4F84-BC23-05FA2DBE03F9Q37906737-6612DABF-224C-46C3-9C4A-213D0E3142BEQ37979862-65897EB0-9260-431E-99C1-AE7259038701Q38221095-3E082A02-26BF-47B9-8547-B01AE0304CDDQ38592676-EE28EE21-3277-4D96-944D-D0B06874177FQ38700961-066AE082-1836-4A1B-8AE4-D53441A55766Q38780346-9F07C37A-42EE-40EA-B4F0-F7303B6DCA17Q39742692-EB726AC5-36EE-48B6-9721-C879F3EF1D1FQ40237578-4E40D69B-8584-4E54-ABDC-BB0716B45DDCQ50224678-6878C3E1-E845-4C3E-ABA9-EE068242BD84Q51168774-9FCBD8D4-57D9-410E-9693-7DCC38043CA0Q57536946-39EF6A28-7185-4EF9-97D3-B286A3EFD267
P2860
Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Elevated serum interferon-alph ...... thirty-six months of therapy.
@en
Elevated serum interferon-alph ...... thirty-six months of therapy.
@nl
type
label
Elevated serum interferon-alph ...... thirty-six months of therapy.
@en
Elevated serum interferon-alph ...... thirty-six months of therapy.
@nl
prefLabel
Elevated serum interferon-alph ...... thirty-six months of therapy.
@en
Elevated serum interferon-alph ...... thirty-six months of therapy.
@nl
P2093
P2860
P356
P1476
Elevated serum interferon-alph ...... r thirty-six months of therapy
@en
P2093
Gabrielle A Morgan
Lauren M Pachman
Sheela Shrestha
P2860
P304
P356
10.1002/ART.24555
P577
2009-06-01T00:00:00Z